After Your Patients With PSMA+ mCRPC Receive Their First ARPI, Be Ready for What's Next1
Identifying Patients
1 ARPI could have been received at any point in your patient’s prostate cancer journey, including in the castration-sensitive setting1,2
For your patients on ARPI, at what point do you begin considering subsequent treatment options?
Patient Profiles
MEET PATIENTS WITH PSMA+ mCRPC WHO ARE ELIGIBLE FOR PLUVICTO
Plan for PLUVICTO after only 1 ARPI, which could have been received at any point in your patient’s journey1,2
Hypothetical patient cases.
GET YOUR PATIENTS ON PLUVICTO PROMPTLY AFTER ONLY 1 ARPI1
3 ways to accelerate the PLUVICTO referral process
mCRPC, metastatic castration-resistant prostate cancer; PET, positron emission technology; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.
*There are over 668 PLUVICTO treatment sites in the US. Please note that the PLUVICTO Treatment Centers listed are only those that have authorized their participation on the PLUVICTO website.4
†Primary plans only; an additional 1-2 days if secondary plan coverage review is required.
Which of your patients with PSMA+ mCRPC could benefit from PLUVICTO now?
ADT, androgen deprivation therapy; BCR, biochemical recurrence; EBRT, external beam radiation therapy; mCSPC, metastatic castration-sensitive prostate cancer; nmCSPC, nonmetastatic castration-sensitive prostate cancer.